The collaboration aims to accelerate API chemical development and shorten timelines, especially for early-stage projects and the biotech segment.
“By adding a renowned CRO partner like SpiroChem to our existing R&D and industrial offering, this fruitful collaboration will strengthen our market position and accelerate our CDMO roadmap,” said Cécile Maupas, chief CDMO officer of EUROAPI.
“Together with EUROAPI’s production technologies, SpiroChem’s recognized capabilities in route scouting will enable us to provide customers with integrated customized solutions to make their chemical drug development shorter, greener and more cost-efficient.”
According to both companies, the agreement will further differentiate their value propositions as customers will benefit from SpiroChem’s early-stage services and knowledge in route scouting, as well as EUROAPI’s development and GMP1 manufacturing capacities and skills.
“Having EUROAPI as a partner brings a substantial value to SpiroChem’s customers who are looking for reliable CDMOs to rapidly and seamlessly scale up the innovative solutions developed by SpiroChem,” said Thomas Fessard, CEO and co-founder of SpiroChem.
“Time is of the essence in early CMC2 and we are confident that this collaboration will greatly benefit our customer base, in particular by accelerating the transition from discovery to development for early-stage projects and the biotech segment.”
